Log in

NASDAQ:MRUS - Merus Stock Price, Forecast & News

$18.99
-0.20 (-1.04 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$18.56
Now: $18.99
$19.30
50-Day Range
$13.52
MA: $16.71
$19.44
52-Week Range
$11.00
Now: $18.99
$20.95
Volume33,324 shs
Average Volume83,180 shs
Market Capitalization$444.52 million
P/E RatioN/A
Dividend YieldN/A
Beta0.1
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRUS
CUSIPN/A
Phone31-0-30-253-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$37.14 million
Book Value$4.77 per share

Profitability

Net Income$-28,660,000.00

Miscellaneous

Employees98
Market Cap$444.52 million
Next Earnings Date4/1/2020 (Estimated)
OptionableNot Optionable

Receive MRUS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.


Merus (NASDAQ:MRUS) Frequently Asked Questions

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

When is Merus' next earnings date?

Merus is scheduled to release their next quarterly earnings announcement on Wednesday, April 1st 2020. View Earnings Estimates for Merus.

What price target have analysts set for MRUS?

6 analysts have issued twelve-month target prices for Merus' stock. Their forecasts range from $16.00 to $35.00. On average, they anticipate Merus' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 26.4% from the stock's current price. View Analyst Price Targets for Merus.

What is the consensus analysts' recommendation for Merus?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merus.

Has Merus been receiving favorable news coverage?

Press coverage about MRUS stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merus earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Merus.

Are investors shorting Merus?

Merus saw a increase in short interest in January. As of January 31st, there was short interest totalling 436,600 shares, an increase of 21.1% from the January 15th total of 360,500 shares. Based on an average daily trading volume, of 119,000 shares, the short-interest ratio is currently 3.7 days. Currently, 2.4% of the shares of the stock are sold short. View Merus' Current Options Chain.

Who are some of Merus' key competitors?

What other stocks do shareholders of Merus own?

Who are Merus' key executives?

Merus' management team includes the folowing people:
  • Dr. Ton Logtenberg, Pres, CEO, Principal Financial Officer & Exec. Director (Age 61)
  • Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
  • Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
  • Mr. John de Kruif Ph.D., CTO & Sr. VP (Age 55)
  • Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 52)

When did Merus IPO?

(MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Who are Merus' major shareholders?

Merus' stock is owned by a number of of retail and institutional investors. Top institutional investors include BVF Inc. IL (13.54%), EcoR1 Capital LLC (7.34%), Driehaus Capital Management LLC (6.13%), Platinum Investment Management Ltd. (0.73%), Oxford Asset Management LLP (0.22%) and Old West Investment Management LLC (0.11%). Company insiders that own Merus stock include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Institutional Ownership Trends for Merus.

Which major investors are selling Merus stock?

MRUS stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL and Tower Research Capital LLC TRC . View Insider Buying and Selling for Merus.

Which major investors are buying Merus stock?

MRUS stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Driehaus Capital Management LLC, Oxford Asset Management LLP, Platinum Investment Management Ltd., Old West Investment Management LLC, Renaissance Technologies LLC, Marshall Wace LLP and Acadian Asset Management LLC. Company insiders that have bought Merus stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Merus.

How do I buy shares of Merus?

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $18.99.

How big of a company is Merus?

Merus has a market capitalization of $444.52 million and generates $37.14 million in revenue each year. The biotechnology company earns $-28,660,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Merus employs 98 workers across the globe.View Additional Information About Merus.

What is Merus' official website?

The official website for Merus is http://www.merus.nl/.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]


MarketBeat Community Rating for Merus (NASDAQ MRUS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  254 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  508
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: 52-Week Highs and Lows

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel